On June 7, 2021, Beijing time, the 2021 ASCO (American Society of Clinical Oncology) annual meeting released an anti-PD-1 monoclonal antibody drug feature independently developed by Junshi Biotech in the form of a "blockbuster research summary" of the plenary meeting. The latest research results of reprizimab combined with chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma. This is the first Chinese local innovative drug research to be selected for the plenary meeting since the official record of the ASCO annual meeting.

At this ASCO annual meeting, a total of 39 related studies of teriprizumab were presented in a concentrated manner, including an oral report at the general assembly, a special oral report, 15 poster presentations and several online abstracts, covering nasopharyngeal cancer, Head and neck cancer, melanoma, lung cancer, stomach cancer, esophageal cancer, liver cancer, cholangiocarcinoma, pancreatic cancer and more than ten types of tumors.